Spark Therapeutics starts common stock offering
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Spark Therapeutics Inc. initiated an underwritten public offering of $300 million of its common stock.
The company also intends to grant the underwriters an option to buy up to an additional 15% of the shares offered.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Co. LLC will act as book-running managers for the offering.
